UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/556,938	02/23/2007	Chunyan Song	EX04-037C-US	7049
63572 7590 03/25/2008 MCDONNELL BOEHNEN HULBERT @ BERGHOFF LLP 300 SOUTH WACKER DRIVE			EXAMINER	
			CARLSON, KAREN C	
SUITE 3100 CHICAGO, IL 60606			ART UNIT	PAPER NUMBER
			1656	
			MAIL DATE	DELIVERY MODE
			03/25/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
Office Action Summers	10/556,938	SONG ET AL.					
Office Action Summary	Examiner	Art Unit					
	Karen Cochrane Carlson, Ph.D.	1656					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	dress				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	J. lely filed the mailing date of this co (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on							
	-· action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the							
closed in accordance with the practice under E							
	,,,,,,,						
Disposition of Claims							
4)⊠ Claim(s) <u>1-25</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdraw	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8)⊠ Claim(s) <u>1-25</u> are subject to restriction and/or e	lection requirement.						
Application Papers							
9)☐ The specification is objected to by the Examine	r.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	ected to. See 37 CF	FR 1.121(d).				
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PT	O-152.				
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of 	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National	Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	te					

The claims have been written using improper Markush language. For example, in Claim 1 (and 20), reference is made to both protein and DNA, In Claim 16, reference is made to cells and to animals. In Claims 14 and 21, no antecedent basis for animal is found in the independent claim for animal. Therefore, the restriction divides the claims into inventions as set forth below.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1, 4-7, 11, and 12, drawn to a method for identifying PTEN/IGF pathway modulating agents via RANBP2, classified in class 435, subclass 7.1.
- II. Claims 1-3, 6, 8-12, 16, and 17, drawn to a method for identifying PTEN/IGF pathway modulating agents via nucleic acid encoding RANBP2 further comprising a secondary assay system comprising cultured cells, classified in class 435, subclass 6.
- III. Claims 1-3, 6, 8-12, 16, 18, and 19, drawn to a method for identifying PTEN/IGF pathway modulating agents via nucleic acid encoding RANBP2 further comprising a secondary assay system comprising animals, classified in class 435, subclass 6.
- IV. Claims 13 and 15, drawn a method of modulating PTEN/IGF pathway comprising contacting a cell with a modulator, classified in class 435, subclass 7.1.
- V. Claims 14, drawn a method of modulating PTEN/IGF pathway comprising administering to an animal a modulator, classified in class 514, subclass 2.
- VI. Claims 20 and 22, drawn to a method of modulating PTEN/IGF pathway in a cell by contacting the cell with an agent that binds RANBP2, classified in class 435, subclass 7.1.

- VIIII. Claim 21, drawn to a method of modulating PTEN/IGF pathway in a cell by administering to an animal an agent that binds RANBP2, classified in class 514, subclass 2.
- IX. Claim 21, drawn to a method of modulating PTEN/IGF pathway in a cell by administering to an animal an agent that binds nucleic acid encoding RANBP2, classified in class 514, subclass 44.
- X. Claims 23-25, drawn to a method for diagnosing disease, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

The methods of Inventions I-X require different products and steps and have different endpoints. Therefore, Inventions 1-X are patentably distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 571-272-0946. The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

Art Unit: 1656

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Kathleen Kerr Bragdon can be reached on 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Karen Cochrane Carlson, Ph.D./ Primary Examiner, Art Unit 1656